An inhibitor, chemically similar to AD-16, successfully suppressed the increase of IL-1β and TNF-α levels in an Alzheimer’s disease model (Munoz et al., 2007), suggesting that AD-16 could also modulate this pathway. The gene discussed is IL1B; the disease is Alzheimer disease.